M. Altai, A. Perols, M. Tsourma, B. Mitran, H. Honarvar et al., Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting, Journal of Nuclear Medicine, vol.57, issue.3, pp.431-437, 2016.
DOI : 10.2967/jnumed.115.162248

URL : http://jnm.snmjournals.org/content/57/3/431.full.pdf

D. Axworthy, J. Reno, M. Hylarides, R. Mallett, L. Theodore et al., Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity, Proceedings of the National Academy of Sciences, vol.2, issue.3, pp.1802-1809, 2000.
DOI : 10.1056/NEJM199308123290703

C. Bodet-milin, A. Faivre-chauvet, T. Carlier, A. Rauscher, M. Bourgeois et al., Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial, Journal of Nuclear Medicine, vol.57, issue.10, pp.1505-1516, 2016.
DOI : 10.2967/jnumed.116.172221

URL : https://hal.archives-ouvertes.fr/inserm-01415668

O. Boerman, M. Kranenborg, E. Oosterwijk, G. Griffiths, W. Mcbride et al., Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate, Cancer Res, vol.59, pp.4400-4405, 1999.

E. Bos, W. Kuijpers, M. Meesters-winters, D. Pham, A. De-haan et al., In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer, Cancer Res, vol.54, pp.3479-86, 1994.

J. Chatal, L. Campion, F. Kraeber-bodéré, S. Bardet, J. Vuillez et al., Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti???Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group, Journal of Clinical Oncology, vol.24, issue.11, pp.1705-1716, 2006.
DOI : 10.1200/JCO.2005.04.4917

J. Chatal, F. Kraeber-bodéré, C. Bodet-milin, and C. Rousseau, Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC)? Current Cancer Ther Rev, pp.54-65, 2016.

A. Forero, P. Weiden, J. Vose, S. Knox, A. Lobuglio et al., Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma, Blood, vol.104, issue.1, pp.227-263, 2004.
DOI : 10.1182/blood-2003-09-3284

E. Frampas, C. Maurel, R. Saëc, P. Mauxion, T. Faivre-chauvet et al., Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide, European Journal of Nuclear Medicine and Molecular Imaging, vol.14, issue.9, pp.2153-64, 2011.
DOI : 10.1158/1078-0432.CCR-07-2031

E. Gautherot, E. Rouvier, L. Daniel, E. Loucif, J. Bouhou et al., Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131 I-labeled bivalent hapten, J Nucl Med, vol.41, pp.480-487, 2000.
DOI : 10.1002/(sici)1097-0142(19971215)80:12+<2618::aid-cncr37>3.0.co;2-d

D. Gold, D. Goldenberg, H. Karacay, E. Rossi, C. Chang et al., A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma, Cancer Research, vol.68, issue.12, pp.4819-4845, 2008.
DOI : 10.1158/0008-5472.CAN-08-0232

URL : http://cancerres.aacrjournals.org/content/canres/68/12/4819.full.pdf

D. Goldenberg, Perspectives on oncologic imaging with radiolabeled antibodies, Cancer, vol.55, issue.S12, pp.2431-2436, 1997.
DOI : 10.1002/1097-0142(19940201)73:3+<896::AID-CNCR2820731322>3.0.CO;2-H

URL : http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19971215)80:12+<2431::AID-CNCR15>3.0.CO;2-D/pdf

D. Goldenberg, R. Sharkey, G. Paganelli, J. Barbet, and J. Chatal, Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, Journal of Clinical Oncology, vol.24, issue.5, pp.823-857, 2006.
DOI : 10.1200/JCO.2005.03.8471

D. Goodwin, C. Meares, G. David, M. Mctigue, M. Mccall et al., Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals, International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, vol.13, issue.4, pp.383-91, 1986.
DOI : 10.1016/0883-2897(86)90015-2

D. Goodwin, C. Meares, M. Mctigue, W. Chaovapong, C. Diamanti et al., Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake, J Nucl Med, vol.33, pp.2006-2019, 1992.

D. Goodwin, C. Meares, N. Watanabe, M. Mctigue, W. Chaovapong et al., Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10- tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy, Cancer Res, vol.54, pp.5937-5983, 1994.

A. Grillo-lópez, Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma, Expert Review of Anticancer Therapy, vol.99, issue.4, pp.485-93, 2002.
DOI : 10.1182/blood.V99.12.4336

S. Halpern and R. Dillman, Problems associated with radioimmunodetection and possibilities for future solutions, J Biol Response Mod, vol.6, pp.235-62, 1987.

K. Herrmann, M. Schottelius, C. Lapa, T. Osl, A. Poschenrieder et al., First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease, Journal of Nuclear Medicine, vol.57, issue.2, pp.248-51, 2016.
DOI : 10.2967/jnumed.115.167361

S. Heskamp, R. Hernandez, J. Molkenboer-kuenen, M. Essler, F. Bruchertseifer et al., Alpha-versus beta-emitting radionuclides for pretargeted radioimmunotherapy of CEA-expressing human colon cancer xenografts, J Nucl Med, 2017.
DOI : 10.2967/jnumed.116.187021

URL : http://europepmc.org/articles/pmc5450366?pdf=render

D. Hnatowich, F. Virzi, and M. Rusckowski, Investigations of avidin and biotin for imaging applications, J Nucl Med, vol.28, pp.1294-302, 1987.

H. Honarvar, K. Westerlund, M. Altai, M. Sandström, A. Orlova et al., Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors, Theranostics, vol.6, issue.1, pp.93-103, 2016.
DOI : 10.7150/thno.12766

J. Houghton, R. Membreno, D. Abdel-atti, K. Cunanan, S. Carlin et al., Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry, Molecular Cancer Therapeutics, vol.16, issue.1, pp.124-157, 2017.
DOI : 10.1158/1535-7163.MCT-16-0503

URL : http://mct.aacrjournals.org/content/molcanther/16/1/124.full.pdf

M. Jain, G. Venkatraman, and S. Batra, Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their Modulation, Clinical Cancer Research, vol.13, issue.5, pp.1374-82, 2007.
DOI : 10.1158/1078-0432.CCR-06-2436

URL : http://clincancerres.aacrjournals.org/content/clincanres/13/5/1374.full.pdf

E. Janevik-ivanovska, E. Gautherot, H. De-boisferon, M. Cohen, M. Milhaud et al., Bivalent Hapten-Bearing Peptides Designed for Iodine-131 Pretargeted Radioimmunotherapy, Bioconjugate Chemistry, vol.8, issue.4, pp.526-559, 1997.
DOI : 10.1021/bc970083h

S. Knox, M. Goris, M. Tempero, P. Weiden, L. Gentner et al., Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/ streptavidin in patients with metastatic colon cancer, Clin Cancer Res, vol.6, pp.406-420, 2000.

F. Kraeber-bodéré, A. Faibre-chauvet, C. Saï-maurel, E. Gautherot, M. Fiche et al., Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft, J Nucl Med, vol.40, pp.198-204, 1999.

F. Kraeber-bodéré, C. Rousseau, C. Bodet-milin, L. Ferrer, A. Faivre-chauvet et al., Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131 I-labeled bivalent hapten in a phase I optimization clinical trial, J Nucl Med, vol.47, pp.247-55, 2006.

F. Kraeber-bodéré, C. Rousseau, C. Bodet-milin, E. Frampas, A. Faivre-chauvet et al., A pretargeting system for tumor PET imaging and radioimmunotherapy, Front Pharmacol, vol.6, p.54, 2015.

M. Kranenborg, O. Boerman, J. Oosterwijk-wakka, M. De-weijert, F. Corstens et al., Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma, Cancer Res, vol.55, pp.5864-5871, 1995.

L. Doussal, J. Gruaz-guyon, A. Martin, M. Gautherot, E. Delaage et al., Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice, Cancer Res. Erratum Cancer Res, vol.5050, pp.3445-526115, 1990.

L. Doussal, J. Chetanneau, A. Gruaz-guyon, A. Martin, M. Gautherot et al., Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response, J Nucl Med, vol.34, pp.1662-71, 1993.

G. Liu, K. Mang-'era, N. Liu, S. Gupta, M. Rusckowski et al., Tumor pretargeting in mice using 99m Tc-labeled morpholino, a DNA analog, J Nucl Med, vol.43, pp.384-91, 2002.

C. Lollo, S. Halpern, R. Bartholomew, G. David, and P. Hagan, Non-covalent antibody-mediated drug delivery, Nuclear Medicine Communications, vol.15, issue.6, pp.483-91, 1994.
DOI : 10.1097/00006231-199406000-00014

S. Lütje, S. Heskamp, A. Cornelissen, T. Poeppel, S. Van-den-broek et al., PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status, Theranostics, vol.5, issue.12, pp.1388-401, 2015.
DOI : 10.7150/thno.13348

W. Mcbride, R. Sharkey, H. Karacay, D. Souza, C. Rossi et al., A Novel Method of 18F Radiolabeling for PET, Journal of Nuclear Medicine, vol.50, issue.6, pp.991-999, 2009.
DOI : 10.2967/jnumed.108.060418

G. Paganelli, M. Bartolomei, M. Ferrari, M. Cremonesi, G. Broggi et al., Y-biotin in Glioma Patients: Phase I Study and Preliminary Therapeutic Results, Cancer Biotherapy & Radiopharmaceuticals, vol.16, issue.3, pp.227-262, 2001.
DOI : 10.1089/10849780152389410

P. Peltier, C. Curtet, J. Chatal, L. Doussal, J. Daniel et al., Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer, J Nucl Med, vol.34, pp.1267-73, 1993.

M. Pimm, H. Fells, A. Perkins, and R. Baldwin, Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody, Nuclear Medicine Communications, vol.9, issue.11, pp.931-972, 1988.
DOI : 10.1097/00006231-198811000-00010

E. Rossi, C. Chang, M. Losman, R. Sharkey, H. Karacay et al., Pretargeting of Carcinoembryonic Antigen-Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells, Clinical Cancer Research, vol.11, issue.19, pp.7122-7131, 2005.
DOI : 10.1158/1078-0432.CCR-1004-0020

E. Rossi, D. Goldenberg, T. Cardillo, W. Mcbride, R. Sharkey et al., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proceedings of the National Academy of Sciences, vol.50, issue.3_Supplement, pp.6841-6847, 2006.
DOI : 10.1158/0008-5472.CAN-05-0420

R. Rossin, P. Verkerk, S. Van-den-bosch, R. Vulders, I. Verel et al., In???Vivo Chemistry for Pretargeted Tumor Imaging in Live Mice, Angewandte Chemie International Edition, vol.34, issue.19, pp.3375-3383, 2010.
DOI : 10.1016/j.nucmedbio.2007.04.001

R. Rossin, T. Läppchen, S. Van-den-bosch, R. Laforest, and M. Robillard, Diels-Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled Antibody, Journal of Nuclear Medicine, vol.54, issue.11, pp.1989-95, 2013.
DOI : 10.2967/jnumed.113.123745

URL : http://jnm.snmjournals.org/content/54/11/1989.full.pdf

P. Salaun, L. Campion, C. Bournaud, A. Faivre-chauvet, J. Vuillez et al., Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement, Journal of Nuclear Medicine, vol.53, issue.8, pp.1185-92, 2012.
DOI : 10.2967/jnumed.111.101865

URL : https://hal.archives-ouvertes.fr/hal-00932253

R. Schoffelen, R. Sharkey, D. Goldenberg, G. Franssen, W. Mcbride et al., Pretargeted Immuno-Positron Emission Tomography Imaging of Carcinoembryonic Antigen-Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts, Molecular Cancer Therapeutics, vol.9, issue.4, pp.1019-1046, 2010.
DOI : 10.1158/1535-7163.MCT-09-0862

R. Schoffelen, O. Boerman, D. Goldenberg, R. Sharkey, C. Van-herpen et al., Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, British Journal of Cancer, vol.20, issue.4, pp.934-976, 2013.
DOI : 10.1200/JCO.2002.11.076

URL : http://www.nature.com/bjc/journal/v109/n4/pdf/bjc2013376a.pdf

R. Schoffelen, W. Woliner-van-der-weg, E. Visser, D. Goldenberg, R. Sharkey et al., Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.9, issue.Suppl 1, pp.1593-602, 2014.
DOI : 10.1089/cbr.2006.21.106

R. Sharkey, W. Mcbride, H. Karacay, K. Chang, G. Griffiths et al., A universal pretargeting system for cancer detection and therapy using bispecific antibody, Cancer Res, vol.63, pp.354-63, 2003.
DOI : 10.2172/898305

URL : https://www.osti.gov/servlets/purl/898305

R. Sharkey, H. Karacay, C. Chang, W. Mcbride, I. Horak et al., Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody, Leukemia, vol.30, issue.6, pp.1064-1073, 2005.
DOI : 10.1007/s00259-002-1090-0

URL : http://www.nature.com/leu/journal/v19/n6/pdf/2403751a.pdf

R. Sharkey, C. Van-rij, H. Karacay, E. Rossi, C. Frielink et al., A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers, Journal of Nuclear Medicine, vol.53, issue.10, pp.1625-1657, 2012.
DOI : 10.2967/jnumed.112.104364

URL : http://jnm.snmjournals.org/content/53/10/1625.full.pdf

D. Stickney, L. Anderson, J. Slater, C. Ahlem, G. Kirk et al., Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma, Cancer Res, vol.51, pp.6650-6655, 1991.

A. Thomas, B. Teicher, and R. Hassan, Antibody???drug conjugates for cancer therapy, The Lancet Oncology, vol.17, issue.6, pp.254-62, 2016.
DOI : 10.1016/S1470-2045(16)30030-4

T. Vag, C. Gerngross, P. Herhaus, M. Eiber, K. Philipp-abbrederis et al., First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers, Journal of Nuclear Medicine, vol.57, issue.5, pp.741-747, 2016.
DOI : 10.2967/jnumed.115.161034

URL : http://jnm.snmjournals.org/content/57/5/741.full.pdf

S. Van-duijnhoven, R. Rossin, S. Van-den-bosch, M. Wheatcroft, P. Hudson et al., Diabody Pretargeting with Click Chemistry In Vivo, Journal of Nuclear Medicine, vol.56, issue.9, pp.1422-1430, 2015.
DOI : 10.2967/jnumed.115.159145

. Bailly, Pretargeting for imaging and therapy in oncological nuclear medicine, EJNMMI Radiopharmacy and Chemistry, vol.54, issue.1, p.6, 2017.
DOI : 10.2967/jnumed.112.115840

URL : https://hal.archives-ouvertes.fr/inserm-01819175

M. Van-essen, A. Sundin, E. Krenning, and D. Kwekkeboom, Neuroendocrine tumours: the role of imaging for diagnosis and therapy, Nature Reviews Endocrinology, vol.45, issue.2, pp.102-116, 2014.
DOI : 10.1007/s00259-013-2369-z

F. Van-schaijk, E. Oosterwijk, A. Soede, M. Broekema, C. Frielink et al., Pretargeting of Carcinoembryonic Antigen-Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen x Anti-Indium-Labeled Diethylenetriaminepentaacetic Acid Antibody, Clinical Cancer Research, vol.11, issue.19, pp.7130-7136, 2005.
DOI : 10.1158/1078-0432.CCR-1004-0006

D. Vugts, G. Visser, and G. Van-dongen, <sup>89</sup>Zr-PET Radiochemistry in the Development and Application of Therapeutic Monoclonal Antibodies and Other Biologicals, Current Topics in Medicinal Chemistry, vol.13, issue.4, pp.446-57, 2013.
DOI : 10.2174/1568026611313040005

Z. Yao, M. Zhang, H. Kobayashi, H. Sakahara, H. Nakada et al., Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase, J Nucl Med, vol.36, pp.837-878, 1995.

Z. Yao, M. Zhang, K. Garmestani, D. Axworthy, R. Mallett et al., Clin Cancer Res, vol.710, issue.10, pp.3137-3183, 2004.

B. Zeglis, K. Sevak, T. Reiner, P. Mohindra, S. Carlin et al., A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry, Journal of Nuclear Medicine, vol.54, issue.8, pp.1389-96, 2013.
DOI : 10.2967/jnumed.112.115840